Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Athena Diagnostics | RCV000518324 | SCV000614170 | uncertain significance | not specified | 2017-01-30 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001829468 | SCV002212026 | likely benign | Nemaline myopathy 2 | 2024-01-10 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004649180 | SCV005146302 | uncertain significance | Inborn genetic diseases | 2024-04-23 | criteria provided, single submitter | clinical testing | The c.17011A>T (p.T5671S) alteration is located in exon 123 (coding exon 121) of the NEB gene. This alteration results from a A to T substitution at nucleotide position 17011, causing the threonine (T) at amino acid position 5671 to be replaced by a serine (S). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Natera, |
RCV001829468 | SCV002084045 | uncertain significance | Nemaline myopathy 2 | 2020-12-29 | no assertion criteria provided | clinical testing |